Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

CD34+ Cell Selection

Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial

Bone Marrow Transplantation volume 25, pages 1165–1174 (2000)Cite this article

Abstract

Tumor contamination of autologous peripheral blood stem/progenitor cell grafts occurs in a substantial proportion of high-risk breast cancer patients, and the possibility that such contamination may contribute to relapse has focused attention on methods for removal of the contaminating cells prior to transplantation. One such approach is positive selection of CD34+ cells. A fully automated immunomagnetic cell selection system has recently been introduced to facilitate the positive selection process. A multicenter randomized clinical trial was designed to evaluate the capacity of CD34+ cells isolated using the fully automated system to support prompt hematopoietic reconstitution following high-dose chemotherapy in high-risk breast cancer patients, as well as to assess the safety and tolerability of the CD34+ cell transplants. In recipients of isolated CD34+ cells, the median time to an absolute neutrophil count ⩾500/μl was 10 days, a value identical to that observed in patients receiving unfractionated apheresis collections. In the isolated CD34+ cell recipients median time to a platelet count ⩾20 000/μl was 12 days, compared with 10 days in the unfractionated cell group. There were no statistically significant differences between the groups in median time to neutrophil or platelet engraftment. Infusion of autologous cells was well tolerated by the study groups. There were no inter-group differences in the incidence of infections, need for platelet transfusions, or duration of hospitalization. Isolated CD34+ cells were high in purity and sufficient in number for use in autologous transplantation. The fully automated immunomagnetic cell selection system affords an efficient and time-saving option for isolation of CD34+cells to be used as autologous grafts in high-risk breast cancer patients, and the isolated CD34+ cells support undelayed hematopoietic reconstitution. Bone Marrow Transplantation (2000) 25, 1165–1174.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Bearman SI, Shpall EJ, Jones RB et al. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer Semin Oncol 1996 23: 60–67

    CAS  PubMed  Google Scholar 

  2. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879

    Article  CAS  PubMed  Google Scholar 

  3. Hortobagyi GN, Buzdar AU, Champlin R et al. Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC)-a randomized trial Proc Am Soc Clin Oncol 1998 17: 12

    Google Scholar 

  4. Rodenhuis S, Richel DJ, van der Wall E et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement Lancet 1998 352: 515–521

    Article  CAS  PubMed  Google Scholar 

  5. Bergh J, . ScandinavianBreastCancerStudyGroup9401 Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy Proc Am Soc Clin Oncol 1999 18: 2A

    Google Scholar 

  6. Bezwoda WR . Randomised, controlled trial of high dose chemotherapy (HD-CNVp) vs. standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer Proc Am Soc Clin Oncol 1999 18: 2A

    Google Scholar 

  7. Peters WP, Rosner G, Vredenburgh J et al. A prospective, randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 Proc Am Soc Clin Oncol 1999 18: 1A

    Google Scholar 

  8. Bezwoda WR, Seymour L, Dansey RD . High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial J Clin Oncol 1995 13: 2483–2489

    Article  CAS  PubMed  Google Scholar 

  9. Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) Proc Am Soc Clin Oncol 1996 15: A149

    Google Scholar 

  10. Lotz JP, Cure H, Janvier M et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): results of the french protocol PEGASE 04 Proc Am Soc Clin Oncol 1999 18: 43A

    Google Scholar 

  11. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the ‘Philadelphia’ Intergroup Study (BPT-1) Proc Am Soc Clin Oncol 1999 18: 1A

    Google Scholar 

  12. Antman KH, Heitjan DF, Hortobagyi GN . High-dose chemotherapy for breast cancer JAMA 1999 282: 1701–1703

    Article  CAS  PubMed  Google Scholar 

  13. Sharp JG, Kessinger A, Vaughan WP et al. Detection and clinical significance of minimal tumor contamination of peripheral stem cell harvests Int J Cell Cloning 1992 10: 92–94

    Article  Google Scholar 

  14. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques Blood 1993 82: 2605–2610

    CAS  PubMed  Google Scholar 

  15. Passos-Coelho J, Ross AA, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide Cancer Res 1994 54: 2366–2371

    CAS  PubMed  Google Scholar 

  16. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment J Clin Oncol 1994 12: 28–36

    Article  CAS  PubMed  Google Scholar 

  17. Simpson SJ, Vachula M, Kennedy MJ et al. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry Exp Hematol 1995 23: 1062–1068

    CAS  PubMed  Google Scholar 

  18. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 1993 341: 85–86

    Article  CAS  PubMed  Google Scholar 

  19. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML Blood 1994 83: 3068–3076

    CAS  PubMed  Google Scholar 

  20. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells Blood 1994 84: 380–383

    CAS  PubMed  Google Scholar 

  21. Shpall EJ, Gee AP, Hogan C et al. Bone marrow metastases Hematol Oncol Clin North Am 1996 10: 321–343

    Article  CAS  PubMed  Google Scholar 

  22. Krause DS, Fackler MJ, Civin CI, May WS . CD34: structure, biology and clinical utility Blood 1996 87: 1–13

    CAS  PubMed  Google Scholar 

  23. Hohaus S, Pforsich M, Murea S et al. Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer Br J Haematol 1997 97: 881–888

    Article  CAS  PubMed  Google Scholar 

  24. Mapara MY, Korner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction Blood 1997 89: 337–344

    CAS  PubMed  Google Scholar 

  25. Roots-Weiβ A, Papadimitriou C, Serve H et al. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems Bone Marrow Transplant 1997 19: 1239–1246

    Article  Google Scholar 

  26. Strauss LC, Trischmann TM, Rowley SD et al. Selection of normal human hematopoietic stem cells for bone marrow transplantation using immunomagnetic microspheres and CD34 antibody Am J Pediatr Hematol Oncol 1991 13: 217–221

    Article  CAS  PubMed  Google Scholar 

  27. Hardwick A, Law P, Kulcinski D et al. Development of a large scale immunomagnetic separation system for harvesting CD34 cells from bone marrow Prog Clin Biol Res 1992 377: 583–589

    CAS  PubMed  Google Scholar 

  28. Papadimitriou CA, Roots A, Koenigsmann M et al. Immunomagnetic selection of CD34+ cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques J Hematother 1995 4: 539–544

    Article  CAS  PubMed  Google Scholar 

  29. Chabannon C, Cornetta K, Lotz J-P et al. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study Br J Cancer 1998 78: 913–921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ishizawa L, Marvin S, Jain R et al. Fully automated CD34+ stem cell selection with integrated cell washing capabilities: performance evaluation Bone Marrow Transplant 1996 17: S129

    Google Scholar 

  31. Brockmeyer C, Deans R, Schwender J et al. CD34+ stem cells released during Isolex selection have membrane integrity with no residual cell surface antibody Blood 1996 88: 244b

    Google Scholar 

  32. Guillermo R, Helwich M, Schneidkraut MJ, Huntenburg CC . CD34+ cell selection using the Isolex 300SA: comparison of chymopapain and PR34+ processes Bone Marrow Transplant 1996 17: S128

    Google Scholar 

  33. Marolleau JP, Dal Cortivo L, Mills B et al. Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent Bone Marrow Transplant 1999 23: 819–826

    Article  CAS  PubMed  Google Scholar 

  34. Burgess J, Mills B, Griffith M et al. Reduction of breast cancer cells in peripheral blood stem cell products by positive selection of CD34+ cells J Hematother 1998 7: 285

    Google Scholar 

  35. Burgess J, Mills B, Griffith M et al. Breast tumor contamination of peripheral blood stem cell harvests. II. Tumor depletion by positive selection of CD34+ cells. (Submitted)

  36. Martino M, Morabito F, Messina G et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients Haematologica 1996 81: 59–61

    CAS  PubMed  Google Scholar 

  37. Zambelli A, Poggi G, Da Prada G et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion Anticancer Res 1998 18: 4705–4708

    CAS  PubMed  Google Scholar 

  38. Somlo G, Doroshow JH, Forman SJ et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival J Clin Oncol 1997 15: 2882–2893

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College of Virginia, Richmond, Virginia, USA

    S Yanovich

  2. Nexell Therapeutics Inc., Irvine, California, USA

    P Mitsky & B Mills

  3. Indiana University Medical Center, Indianapolis, Indiana, USA

    K Cornetta

  4. Oregon Health Sciences University, Portland, Oregon, USA

    RT Maziarz

  5. Medical City Dallas Hospital, Dallas, Texas, USA

    C Rosenfeld

  6. Yale University School of Medicine, New Haven, Connecticut, USA

    DS Krause & B Burtness

  7. Hôpital Tenon, Paris, France

    J-P Lotz

  8. Lutheran General Cancer Care Center, Park Ridge, Illinois, USA

    JD Bitran

  9. University of Chicago Medical Center, Chicago, Illinois, USA

    S Williams

  10. New York Blood Center, Valhalla, New York, USA

    R Preti

  11. City of Hope National Medical Center, Duarte, California, USA

    G Somlo

Authors
  1. S Yanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Mitsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Cornetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. RT Maziarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Rosenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. DS Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J-P Lotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. JD Bitran
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Preti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G Somlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B Burtness
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. B Mills
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yanovich, S., Mitsky, P., Cornetta, K. et al. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplant 25, 1165–1174 (2000). https://doi.org/10.1038/sj.bmt.1702415

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702415

Keywords

This article is cited by

Search

Advanced search

Quick links